________________________________________________________________________________
Diabetes Mellitus and Risks of Dual Blockade of the Renin-Angiotensin-Aldosterone System
Ferrán Catalá-López a,b* and Diego Macías Saint-Gerons a
aDivisión de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España
bCentro Superior de Investigación en Salud Pública (CSISP), Valencia, España
________________________________________________________________________________
Referencias bibliográficas de los nueve ensayos incluidos
1. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised
controlled trial of dual blockade of renin-angiotensin system in patients with hypertension,
microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril
microalbuminuria (CALM) study. BMJ. 2000;321:1440-4.
2. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al. Long-term
dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II
3. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of
the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and
hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-8.
4. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med.
5. Telmisartan (Micardis®). Combined clinical and statistical review. Bethesda: U.S. Food and Drug
Administration; 2009 [citado 25 Abr 2012]. Disponible en:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiov
ascularandRenalDrugsAdvisoryCommittee/UCM173536.pdf
6. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor
blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in
diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-50.
7. Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL. Aliskiren as add-on therapy in the
treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT
combination: a placebo-controlled study. Am J Cardiovasc Drugs. 2011;11:327-33.
8. Titan SM, Vieira JM Jr, Dominguez WV, Barros RT, Zatz R. ACEI and ARB combination
therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a
double-blind randomized clinical trial. Clin Nephrol. 2011;76:273-83.
9. Parving HH, Brenner BM, McMurray JJ, De Zeeuw D, Haffner SM, Solomon SD, et al.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes (ALTITUDE). N Engl J Med. 2012
3 Nov [Epub ahead of print]. DOI: 10.1056/NEJMoa1208799.
10. FDA Drug Safety Communication: New warning and contraindication for blood pressure
medicines containing aliskiren (Tekturna). Bethesda: U.S. Food and Drug Administration; 2012
[citado 22 Abr 2012]. Disponible en: http://www.fda.gov/drugs/drugsafety/ucm300889.htm
Análisis de sensibilidad (eliminación del estudio ALTITUDE)
SURF LIFE SAVING AUSTRALIA POLICY STATEMENT INTRODUCTION Asthma is a common condition in Australia, affecting 12.8% of the population1. It is more common in school aged children than adults2. Currently there is no cure for asthma but in the majority of cases it can be well controlled so that the person with asthma has no limitations in their life. There are many examples of stat
FINAL TEXT: 24-July-2012 ARCOXIA® W (etoricoxib) PRESCRIBING INFORMATION Refer to Summary of Product Characteristics before prescribing Adverse events should be reported. Reporting forms and information can be found at reported to MSD (tel: 01992 467272). PRESENTATION Tablets: 30 mg, 60 mg, 90 mg and 120 mg tablets each containing 30 mg, 60 mg, 90 mg or 120 mg of etoric
________________________________________________________________________________
Diabetes Mellitus and Risks of Dual Blockade